Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct;13(5):238-244.
doi: 10.14740/jh1303. Epub 2024 Oct 21.

Primary Refractory Discordant Diffuse Large B-Cell and Classical Hodgkin Lymphoma

Affiliations
Case Reports

Primary Refractory Discordant Diffuse Large B-Cell and Classical Hodgkin Lymphoma

Yuxin Bai et al. J Hematol. 2024 Oct.

Abstract

Discordant lymphomas are defined as two or more distinct pathological lymphomas occurring in the same patient. Due to the rarity of discordant lymphomas, which is due in large part to the difficulty in establishing the diagnosis, the literature is limited to small case series and case reports. Consequently, guidelines on therapeutic strategies are lacking. This article presented a case of primary refractory discordant large B-cell lymphoma and classic Hodgkin lymphoma in a young man based on cervical node and mediastinal mass biopsy, respectively. This case illustrates the difficulty in establishing the diagnosis, which ultimately warranted a high index of clinical suspicion and pursuit of multiple sequential biopsies, as well as a novel treatment strategy using an immune checkpoint inhibitor.

Keywords: Checkpoint inhibitor; Classical Hodgkin lymphoma; Discordant lymphoma; Large B-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Clinical-pathologic summary of events. LBCL: large B-cell lymphoma; CHL: classical Hodgkin lymphoma; DA-EPOCH-R: dose-adjusted EPOCH-R; DLBCL: diffuse large B-cell lymphoma; PET/CT: positron emission tomography/computed tomography; EPOCH-R: etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; GDP: gemcitabine, dexamethasone, cisplatin; CAR: chimeric antigen receptor.
Figure 2
Figure 2
First instance of lymphoma shown in a biopsy of a left neck lymph node. The revised diagnosis is of a diffuse large B-cell lymphoma of germinal center phenotype (CD10-, BCL6+, MUM1-). The architecture of the lymph node parenchyma is effaced by sheets of large rounded lymphoid cells (H&E stain × 400). There is diffuse immunoreactivity for CD20 and PAX5, and patchy staining for CD30 (× 200, insert: low power). There was no positivity for CD15 or CD23. Tumor cells are PDL1+. H&E: hematoxylin and eosin; PDL1: programmed death ligand-1; BCL6: B-cell lymphoma 6; MUM1: multiple myeloma 1; PAX5: paired box 5.
Figure 3
Figure 3
Second instance of lymphoma shown in a biopsy of a mediastinal mass. The revised diagnosis is of a classic Hodgkin lymphoma. There are scattered large cells with Reed Sternberg and Hodgkin morphology (arrows) scattered in an eosinophil rich mixed lymphoid background (H&E stain, × 400). Tumor cells (arrows) that do not show immunoreactivity for CD20 (× 400), are positive for PAX5 (× 400), CD30 (× 400) and negative for CD15 (insert, background inflammatory cells positive). Tumor cells are PDL1+. H&E: hematoxylin and eosin; PDL1: programmed death ligand-1; PAX5: paired box 5.

Similar articles

Cited by

References

    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G. et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2. - DOI - PMC - PubMed
    1. Kim H. Composite lymphoma and related disorders. Am J Clin Pathol. 1993;99(4):445–451. doi: 10.1093/ajcp/99.4.445. - DOI - PubMed
    1. Mead GM, Kushlan P, O'Neil M, Burke JS, Rosenberg SA. Clinical aspects of non-Hodgkin's lymphomas presenting with discordant histologic subtypes. Cancer. 1983;52(8):1496–1501. doi: 10.1002/1097-0142(19831015)52:8<1496::aid-cncr2820520827>3.0.co;2-1. - DOI - PubMed
    1. Zarate-Osorno A, Medeiros LJ, Kingma DW, Longo DL, Jaffe ES. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol. 1993;17(2):123–132. - PubMed
    1. Aussedat G, Traverse-Glehen A, Stamatoullas A, Molina T, Safar V, Laurent C, Michot JM. et al. Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. Br J Haematol. 2020;189(2):244–256. doi: 10.1111/bjh.16331. - DOI - PubMed

Publication types

LinkOut - more resources